# Cardiac Effects of Spiolto®/Respimat® in Patients With Congestive Heart Failure and COPD

> **NCT02812862** · PHASE4 · WITHDRAWN · sponsor: **RWTH Aachen University**

## Conditions studied

- COPD

## Interventions

- **DRUG:** Spiolto® Respimat® (Tiotropium / Olodaterol)

## Key facts

- **NCT ID:** NCT02812862
- **Lead sponsor:** RWTH Aachen University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-08
- **Primary completion:** 2017-08
- **Final completion:** 2018-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Rationale obsolete
- **Last updated:** 2022-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02812862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02812862, "Cardiac Effects of Spiolto®/Respimat® in Patients With Congestive Heart Failure and COPD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02812862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*